课题基金 / 基金详情

Serum soluble interleukin-2 receptor and immunohistochemical staining of IL-2R/Tac antigen in gastric cancer

Serum soluble interleukin-2 receptor and immunohistochemical staining of IL-2R/Tac antigen in gastric cancer
胃癌血清可溶性白细胞介素2受体及IL-2R/Tac抗原免疫组化染色
批准号:
11671269
负责人:
MURAKAMI Saburo
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2002

项目摘要

项目成果

MURAKAMI Saburo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In the present study, we investigated the clinical significance of serum sIL-2R in patients with early gastric cancer. 215 patients with gastric cancer were enrolled in this study. Levels of serum soluble IL-2R were measured by an enzyme-linked immunosorbent assay. The levels of sIL-2R in cases with metastatic lymph nodes were significantly higher than those without metastatic lymph nodes. Moreover, Levels of serum sIL-2R in 74 patients with early gastric cancer were measured. Five of these 6 cases with metastatic lymph nodes demonstrated positive levels of serum soluble IL-2R, while 43 of 68 cases without metastatic lymph nodes demonstrated negative levels of serum sIL-2R. In the tissues obtained from 19 cases, immunohistochemical staining was performed with mouse anti-human interleukin-2 receptor antibody. 13 of 19 cases showed Il-2R positive cells in gastric cancer tissues. Similarly, Il-2R positive cells were recognized in the tissues of metastatic lymph nodes. These results may suggest that activated T lymphocytes infiltrating into the cancer tissues play an atitumor role and release a large amount of sIL-2R, resulting the high levels of serum sIL-2R in patients with gastric cancer. Moreover, we could get the same results in colorectal cancer as in gastric cancer. According to these data, T-lymphocytes, stimulated by humoral mediator released from cancer cells, would become to be activated T-lymphocytes, resulting in the anti-tumor effects in gastrointestinal cancer.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
村上三郎 その他: "早期胃癌患者におけるリンパ節転移予知因子としての血中可溶性IL-2R値."外科治療. 84・2. 241-242 (2001)
Saburo Murakami 等:“可溶性 IL-2R 水平作为早期胃癌患者淋巴结转移的预测因子。”84・2(2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Sakata H, Murakami S, Hirayama R: "Serum soluble IL-2R and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer"International Journal of Clinical Oncology. 7・5. 312-317 (2002)
Sakata H、Murakami S、Hirayama R:“结直肠癌中的血清可溶性 IL-2R 和 IL-2R/Tac 抗原的免疫组织化学染色”国际临床肿瘤学杂志 7・5(2002 年)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Murakami S, Sakata H, Tsuji Y, Hirayama R, et al.: "Serum soluble IL-2R as a predictor of lymph node metastasis in early gastric cancer"Digestive Surgery. 19・1. 9-14 (2002)
Murakami S、Sakata H、Tsuji Y、Hirayama R 等:“血清可溶性 IL-2R 作为早期胃癌淋巴结转移的预测因子”19・1(2002 年)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Saburo Murakami, et al.: "Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer"Digestive Surgery. Vol19(in press). (2002)
Saburo Murakami 等人:“血清可溶性白细胞介素 2 受体作为早期胃癌淋巴结转移的预测因子”消化外科。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
6
    Pathology and function of immuno-reactive cells for cell-mediated immunity in intestinal immune system of gastric and colorectal cancer
    • 批准号:
      15591438
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.73万
    • 财政年份:
      2003
    • 负责人:
      MURAKAMI Saburo
    • 依托单位:
    国内基金
    海外基金
    IL-2Rβ编程巨噬细胞极化失衡介导孕期强的松暴露所致成年子代滑膜炎易感
    • 批准号:
      82373969
    • 项目类别:
      面上项目
    • 资助金额:
      49万元
    • 批准年份:
      2023
    • 负责人:
      倪曲波
    • 依托单位:
    可溶性IL-2Rα激活小胶质细胞诱导多发性硬化发生发展的机制研究
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      陆慧
    • 依托单位:
    IL-2Rα通过自分泌途径靶向特定星形胶质细胞亚型调节脑缺血后丘脑-皮层连接重塑的机制研究
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      52万元
    • 批准年份:
      2022
    • 负责人:
      赵海苹
    • 依托单位:
    Glcα1,2Galβ1-糖基化修饰:IL-2/IL-2R介导JAK-STAT信号途径激活的关键?
    • 批准号:
      82170541
    • 项目类别:
      面上项目
    • 资助金额:
      55.00万元
    • 批准年份:
      2021
    • 负责人:
      魏红山
    • 依托单位: